FDA vaccine advisers unanimously endorsed Moderna’s mRNA-1010, voting that benefits outweigh risks for adults ages 50–64 and separately for those 65 and older. The Vaccines and Related Biological Products Advisory Committee vote sets up what could be a near-term regulatory decision, with FDA action expected by Aug. 5.